Iovance Biotherapeutics to Present at Upcoming Conferences
Rhea-AI Summary
Iovance Biotherapeutics (NASDAQ: IOVA) announced senior leadership will present at two upcoming investor conferences in March 2026. Presentations: TD Cowen 46th Annual Healthcare Conference on March 2, 2026 at 9:50 a.m. ET and Barclays 28th Annual Global Healthcare Conference fireside chat on March 11, 2026 at 9:30 a.m. ET.
Live and archived webcasts will be available via the company investor events page at the provided webcast link.
Positive
- None.
Negative
- None.
News Market Reaction – IOVA
On the day this news was published, IOVA declined 1.04%, reflecting a mild negative market reaction. Argus tracked a trough of -4.3% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $15M from the company's valuation, bringing the market cap to $1.46B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IOVA showed a modest gain of 1.32% with elevated volume, while momentum data flagged only GERN moving, down -2.329999953508377%. Broader biotech peers in the watch list showed mixed single-day moves, suggesting today’s activity appears more stock-specific than a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Clinical data update | Positive | +30.8% | Positive early lifileucel data in UPS and DDLPS with 50% ORR. |
| Feb 24 | Earnings and updates | Positive | +30.8% | Strong Q4 and 2025 revenue, improved gross margin, and cash runway into Q3 2027. |
| Feb 20 | Inducement grants | Neutral | +0.7% | Small inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). |
| Feb 11 | Earnings call date | Neutral | -3.1% | Announcement of date and time for Q4 and full-year 2025 results call. |
| Feb 05 | Real-world data | Positive | +7.2% | Real-world Amtagvi data showing 44% ORR and 73% disease control in melanoma. |
Recent clinical and earnings releases have generally triggered strong positive price reactions, indicating the stock has responded favorably to major fundamental updates.
Over recent months, Iovance reported several notable milestones. A Feb 24, 2026 clinical trial update in soft tissue sarcomas and strong Q4 and full-year 2025 results each coincided with a 30.8% one-day gain. Earlier, real-world Amtagvi data on Feb 5, 2026 accompanied a 7.2% move. Smaller items such as inducement grants on Feb 20, 2026 and announcing the earnings date on Feb 11, 2026 saw relatively muted single-digit reactions. Today’s conference appearances fit into an ongoing cadence of investor and scientific communication.
Market Pulse Summary
This announcement highlights Iovance’s plan to engage investors and analysts through upcoming TD Cowen and Barclays healthcare conferences, with presentations on March 2, 2026 and March 11, 2026. In context, the company has recently reported strong clinical data and revenue growth, which previously drew significant market attention. Investors may focus on how management frames commercial progress, pipeline timelines, and capital needs during these events, comparing messaging to the latest clinical and regulatory disclosures.
Key Terms
tumor infiltrating lymphocyte medical
AI-generated analysis. Not financial advice.
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
- TD Cowen 46th Annual Healthcare Conference
Presentation: March 2, 2026 at 9:50 a.m. ET
Boston, MA
- Barclays 28th Annual Global Healthcare Conference
Fireside Chat: March 11, 2026 at 9:30 a.m. ET
Miami, FL
The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
FAQ
When will Iovance (IOVA) present at the TD Cowen Healthcare Conference in 2026?
What is the schedule for Iovance (IOVA) at the Barclays Global Healthcare Conference March 2026?
How can investors watch Iovance (IOVA) conference presentations in March 2026?
Which Iovance (IOVA) executives will present at the March 2026 conferences?
Will Iovance (IOVA) archive the March 2026 conference webcasts for later viewing?
